I would begin with the observation that putting in the refusal criteria when a company applies to get on market is already something that the minister can do, or the GIC can do, under the current act. We can, in regulation, stipulate grounds of refusal without having this as an addition.
Having said that, there is a very important policy discussion here—that is, do you want to tie the refusal of an authorization of an important life-saving drug to a transparency measure, or is it a better discipline to go with fines because patients do need them? Really, it's in making the regulations about why you would refuse a drug submission that the conversation would be held—but in regulations.